Pethema Foundation
Clinical trials sponsored by Pethema Foundation, explained in plain language.
-
New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
Disease control CompletedThis study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for older AML patients: triple drug combo aims to control disease and prevent relapse
Disease control CompletedThis study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …
Phase: PHASE1, PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill combo aims to improve AML treatment in Non-FLT3 patients
Disease control CompletedThis phase 2 trial tested whether adding the targeted drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that does not have a FLT3 mutation. 273 patients were randomly assigned to receive either quizartinib or a placebo alongs…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC